Company overview
JPT Peptide Technologies specializes in custom peptide synthesis, peptide libraries, pools, and microarrays for pharmaceutical R&D, cell therapy, vaccines, and drug discovery. With over 20 years of expertise from facilities in Berlin, Germany, they offer scalable production from micro-scale to large-scale, supporting immune monitoring, epitope mapping, and proteomics. JPT is DIN EN ISO 9001:2015 certified and GCLP audited, serving pharma, biotech, academia, and non-profits globally.
JPT Peptide Technologies is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include peptide synthesis, peptide libraries, custom peptides, cell therapy peptides, vaccine development.
Products and technologies associated with JPT Peptide Technologies include Synthesis — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.jpt.com
- Markets served
- United States & Americas
- Keywords
- peptide synthesis, peptide libraries, custom peptides, cell therapy peptides, vaccine development
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What peptide synthesis capabilities does JPT offer?
- JPT provides custom peptide synthesis from micro-scale (10-150 nmol) for screening, mid-scale (1 mg-1 g) with modifications, to large-scale (>1 g), using Fmoc SPPS, SPOT synthesis, and ligation for long sequences, with purities from crude to >98%.
- What regulatory certifications does JPT hold?
- JPT is DIN EN ISO 9001:2015 certified and GCLP audited, with production in state-of-the-art Berlin laboratories compliant for clinical immune monitoring, cell therapy, and vaccine development.
- What geographies does JPT serve?
- Based in Berlin, Germany, JPT serves global clients in pharmaceutical and biotechnology industries, universities, governmental, and non-profit organizations worldwide.
Related editorial coverage
- Trump's Executive Order on Childhood Vaccine Schedules: Impact on Pharmaceutical Companies
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
